CG Oncology (CGON) Other Operating Expenses (2025 - 2026)

CG Oncology's (CGON) quarterly Other Operating Expenses came in at $3.0 million in Q1 2026, down 3.52% on a QoQ basis from $3.1 million in Q4 2025.

Analysis

CG Oncology (CGON) Other Operating Expenses (2025 - 2026) Analysis & Trends

CG Oncology (CGON) has 2 years of Other Operating Expenses data on file, last reported at $3.0 million in Q1 2026.

Quarterly Other Operating Expenses changed N/A year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.6 million (changed N/A YoY) and the FY2025 annual result came in at $4.6 million, changed N/A from the prior year.
Other Operating Expenses eased to $3.0 million in Q1 2026, from $3.1 million in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $3.1 million in Q4 2025 to a low of $1.6 million in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.31 Bn	131.46 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.65 Bn	77.66 Bn	3.93 Bn
3	Argenx Se	63.46 Bn	58.27 Bn	1.37 Bn
4	Moderna	57.94 Bn	52.80 Bn	52.00 Mn
5	Revolution Medicines	44.05 Bn	44.05 Bn	-
6	BeOne Medicines	39.96 Bn	34.86 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.16 Bn	31.85 Bn	992.69 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn
10	CG Oncology	6.56 Bn	6.56 Bn	-2.77 Mn

Historic Data

Download Data